Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2 -mutant Glioma.

Kristina A Fanucci Mary Jo Pilat Derek Shyr Yu Shyr Scott A Boerner Jing Li Diane E Durecki Jan Drappatz Vinay K Puduvalli Frank Scott Lieberman Javier Gonzalez Pierre Giglio Susan Percy Ivy Ranjit S Bindra Antonio Omuro Patricia M LoRusso

Published in: Cancer research communications (2023)

-mutant gliomas.

Keyphrases